DrugPatentWatch Database Preview
Drugs in Development Information for TAK-228
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for TAK-228?
TAK-228 is an investigational drug.
There have been 329 clinical trials for TAK-228.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.
The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).
There are twenty-nine US patents protecting this investigational drug and two hundred and sixty-two international patents.
Summary for TAK-228
| US Patents | 29 |
| International Patents | 262 |
| US Patent Applications | 95 |
| WIPO Patent Applications | 48 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2016-06-01) |
| Vendors | 59 |
Recent Clinical Trials for TAK-228
| Title | Sponsor | Phase |
|---|---|---|
| Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) | National Cancer Institute (NCI) | Phase 2 |
| Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) | Southwest Oncology Group | Phase 2 |
| Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/Chronic Primary Immune Thrombocytopenia | Millennium Pharmaceuticals, Inc. | Phase 2 |
Clinical Trial Summary for TAK-228
Top disease conditions for TAK-228
Top clinical trial sponsors for TAK-228
US Patents for TAK-228
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| TAK-228 | Start Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | Start Trial |
| TAK-228 | Start Trial | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN) | Start Trial |
| TAK-228 | Start Trial | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (La Jolla, CA) | Start Trial |
| TAK-228 | Start Trial | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| TAK-228 | Start Trial | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for TAK-228
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TAK-228 | Australia | 2014348657 | 2033-11-13 | Start Trial |
| TAK-228 | Australia | 2017245411 | 2033-11-13 | Start Trial |
| TAK-228 | Canada | 2929181 | 2033-11-13 | Start Trial |
| TAK-228 | China | 105899232 | 2033-11-13 | Start Trial |
| TAK-228 | Eurasian Patent Organization | 201690987 | 2033-11-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
